Inovio Pharmaceuticals (INO) EBT (2016 - 2025)
Historic EBT for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$20.7 million.
- Inovio Pharmaceuticals' EBT rose 2127.37% to -$20.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.9 million, marking a year-over-year increase of 2330.59%. This contributed to the annual value of -$107.8 million for FY2024, which is 2021.03% up from last year.
- According to the latest figures from Q3 2025, Inovio Pharmaceuticals' EBT is -$20.7 million, which was up 2127.37% from -$22.5 million recorded in Q2 2025.
- Over the past 5 years, Inovio Pharmaceuticals' EBT peaked at -$19.5 million during Q4 2024, and registered a low of -$108.5 million during Q2 2022.
- Over the past 5 years, Inovio Pharmaceuticals' median EBT value was -$35.5 million (recorded in 2023), while the average stood at -$46.9 million.
- In the last 5 years, Inovio Pharmaceuticals' EBT plummeted by 38746.36% in 2021 and then skyrocketed by 6724.85% in 2023.
- Quarter analysis of 5 years shows Inovio Pharmaceuticals' EBT stood at -$106.9 million in 2021, then skyrocketed by 49.07% to -$54.5 million in 2022, then surged by 54.09% to -$25.0 million in 2023, then rose by 21.94% to -$19.5 million in 2024, then fell by 5.85% to -$20.7 million in 2025.
- Its EBT stands at -$20.7 million for Q3 2025, versus -$22.5 million for Q2 2025 and -$24.2 million for Q1 2025.